Incidence of grade ≥3 AEs during consolidation. Comparison of myeloablative vs nonmyeloablative therapies is as follows: thrombocytopenia, 81% vs 85%; neutropenia, 79% vs 82%; febrile neutropenia, 53% vs 53%; anemia, 53% vs 76%; lymphopenia, 54% vs 38%; oral mucositis, 37% vs 12%; hyperglycemia, 3% vs 18%; hypophosphatemia, 11% vs 12%; generalized muscle weakness, 16% vs 0%; fatigue, 11% vs 0%; anorexia, 11% vs 0%; hypertension, 11% vs 9%; cognitive disturbance, 8% vs 0%; delirium, 8% vs 0%, respectively. Although the incidence of grade ≥3 cytopenias and febrile neutropenia were comparable between the consolidative arms, 2 patients on the myeloablative arm experienced grade 4 sepsis vs none in the nonmyeloablative arm. Furthermore, 3 patients in the myeloablative arm experienced grade 3 cognitive disturbances vs none in the nonmyeloablative arm; 1 of these occurred in a patient within 3 months after ending treatment, but the other 2 patients had these events occur 16 and 24 months after the end of treatment. Furthermore, among 108 patients who received induction therapy, the numbers of patients with dose modifications, omissions, or delays due to any of the 4 drugs administered were 84 (78%), 38 (35%), and 73 (68%), respectively. The numbers of patients with dose modifications during MTR induction followed by single administration of high-dose cytarabine induction were 81 (75%), 30 (28%), 1 (<1%), and 6 (6%) for each agent, respectively; the numbers of patients with dose omissions were 21 (19%), 24 (22%), 10 (9%), and 1 (<1%) for each agent, respectively; and the numbers of patients with dose delays were 57 (53%), 26 (24%), 18 (17%), and 6 (6%) for each agent, respectively.